Key Takeaways:
Enterprise Therapeutics Ltd. announced its lead cystic fibrosis candidate, ETD001, produced a statistically significant 3.4 percentage point improvement in lung function versus placebo in a Phase 2 study, a key victory in a therapeutic area where many larger drugmakers have failed.
“The results are a highly encouraging clinical milestone and a strong validation of Enterprise’s approach,” Greg Smith, chief executive of parent company IP Group PLC (LSE:IPO), said in a statement, highlighting the meaningful improvement in a population with significant unmet need.
The trial enrolled 57 patients with cystic fibrosis (CF) who are ineligible for or not receiving CFTR modulator therapies, a group representing about 10 percent of the total CF population. After receiving the inhaled 4.5 mg dose twice daily for 28 days, patients showed the 3.4 point gain in percent predicted forced expiratory volume in one second (ppFEV1), a standard measure of lung function. The result was clinically relevant and statistically significant with a p-value of 0.0053.
The positive data provides a potential breakthrough for the 10 percent of CF patients who lack effective treatments and have worse outcomes than those who can take CFTR modulators like Vertex Pharmaceuticals' Alyftrek. While the 3.4 point gain is below the double-digit improvements seen with modulators, it addresses a patient group with no alternatives. The epithelial sodium channel (ENaC) has been a target for years, but major pharmaceutical companies including Vertex, Boehringer Ingelheim, AstraZeneca, and Novartis have all terminated their ENaC inhibitor programs after failing to show clinical benefit in mid-stage trials, often citing issues with dosing and drug delivery.
Enterprise Therapeutics believes ETD001 can succeed due to its design for prolonged retention in the airways. The company reported that a single low dose enhanced mucus clearance in sheep airways for at least 16 hours, a long duration of action it sees as key to therapeutic success. The drug was also found to be safe and well-tolerated.
An exploratory analysis of the Phase 2 data showed that participants were three times more likely to see an improvement in lung function when receiving ETD001 compared to placebo.
The positive results de-risk the asset for IP Group, which invests in early-stage science and technology companies. The success could attract partnership or acquisition interest from larger pharmaceutical firms looking to enter the space.
Enterprise plans to advance ETD001 into longer-duration Phase 2b dose-ranging studies and to evaluate its effect in combination with CFTR modulators. The company also intends to explore the drug's potential in non-CF bronchiectasis, another muco-obstructive lung disease. Full results from the trial will be presented at the European Cystic Fibrosis Society conference in Lisbon in June.
This article is for informational purposes only and does not constitute investment advice.
